I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
Pyridine N-oxide is used in the treatment of Kayser's disease. It is widely used in chemical industry. It can act as catalytic agent.
J. V. Quagliano; J. Fujita; G. Franz; D. J. Phillips; J. A. Walmsley; S. Y. Tyree. The Donor Properties of Pyridine N-Oxide. J. Am. Chem. Soc.1961, 83, (18), 3770-3773.
Mild oxidant for conversion of unactivated alkyl halides to aldehydes or ketones: J. Org. Chem., 22, 1135 (1957); 35, 244 (1970); Tetrahedron, 33, 1845 (1977). Substituted acetic acids and their anhydrides: J. Org. Chem., 38, 3737 (1973), as well as ɑ-bromo and ɑ-chloro acids: J. Org. Chem., 31, 3058 (1966); J. Am. Chem. Soc., 89, 4968 (1967), can undergo oxidative decarboxylation to aldehydes and ketones.
Gefahrenhinweise (EU): H301-H315-H319-H335
Toxic if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation.
Do not breathe dust/fume/gas/mist/vapours/spray. Obtain special instructions before use. Wear protective gloves. IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.